<DOC>
	<DOCNO>NCT00273273</DOCNO>
	<brief_summary>The purpose project study pharmacokinetics once-daily antiretroviral medication use treat adolescent young adult HIV infection .</brief_summary>
	<brief_title>PK Once Daily ART Containing Tenofovir Atazanavir/Ritonavir</brief_title>
	<detailed_description>Once-daily antiretroviral therapy use treat adolescent young adult HIV-1 infection . When new antiretrovirals ( ARVs ) develop , information kinetics collect adult , child , often adolescent age group under-represented initial even later pharmacokinetics study , specific data appropriate drug dos use adolescent may lack ; assume receive adult dose . Furthermore , new drug use combination regimens , information becomes available drug interaction might initially anticipate . This information usually generate study adult , little specific information child adolescent . This open-label , 24-hour , single-dose pharmacokinetic study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age &gt; 18 year &lt; 25 year . Confirmed diagnosis HIV1 infection define one positive assay support documentation subject 's medical record . The result may follow : HIV1 DNA PCR , HIV1 RNA PCR ( &gt; 5,000 copies/ml ) , Standard ELISA confirmatory western blot perform 18 month age , HIV culture . CD4 cell count : restriction . Viral load : restriction . Current treatment stable antiretroviral combination therapy least 3 active drug minimum 28 day . The treatment regimen start changed purpose participation study . Rather , study measure kinetics drug patient receive therapy direction treat physician . Regimen must prescribe FDAapproved dos age . Regimens allow : Atazanavir 300 mg po daily plus ritonavir 100 mg po daily , Tenofovir 300 mg po daily , plus At least one antiretroviral medication prescribe FDAapproved dose age , exclude protease inhibitor NNRTIs . Ability willingness contact study personnel daily two day prior pharmacokinetics visit , take antiretroviral medicine time morning daily least 3 day ( one day day PK study visit ) , ability willingness return clinic day observe administer dose followup measurement plasma drug concentration . Ability willingness provide write informed consent . Pregnancy . Active therapy malignancy . Known presence gastrointestinal disease would interfere drug administration absorption . Grade 3 high ALT AST . Grade 3 high Creatinine . Concurrent treatment another protease inhibitor nonnucleoside analogue reverse transcriptase inhibitor . No evidence anemia great Grade 1 accord ATN Toxicity Table Grading Severity Adolescent Adverse Experiences ( see Chapter 11 ATN MOGO ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Atazanavir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>tenofovir</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>